Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our high-tech, dedicated method is applied to construct targeted libraries for receptors.
Fig. 1. The sreening workflow of Receptor.AI
This process includes extensive molecular simulations of the receptor in its native membrane environment, along with ensemble virtual screening that accounts for its conformational mobility. In the case of dimeric or oligomeric receptors, the entire functional complex is modelled, identifying potential binding pockets on and between the subunits to encompass all possible mechanisms of action.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
O43603
UPID:
GALR2_HUMAN
Alternative names:
-
Alternative UPACC:
O43603; A5JUU4; Q32MN8
Background:
Galanin receptor type 2, encoded by the gene O43603, serves as a critical receptor for the hormones galanin, GALP, and spexin-1. It operates through G proteins, activating the phospholipase C/protein kinase C pathway and inhibiting adenylyl cyclase, showcasing its pivotal role in cellular signaling.
Therapeutic significance:
Understanding the role of Galanin receptor type 2 could open doors to potential therapeutic strategies. Its involvement in key signaling pathways highlights its potential as a target for drug discovery, aiming to modulate its activity for therapeutic benefits.